Zydus Cadila is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain. With a core competence in the field of healthcare, Zydus Cadila provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to wellness products.
Recently, the group launched Exemptia, the world’s first biosimilar for Adalimumab, the largest selling therapy worldwide for inflammatory arthritis. Zydus is also the only Indian pharma company to launch its own patented NCE – Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.
For the treatment of postmenopausal women with severe osteoporosis who are at high risk of fracture or who
have failed or are intolerant to previous osteoporosis therapy.
Osteoporosis means “porous bone.” If you look at healthy bone under a microscope, you will see that parts of it look like a honeycomb. If you have osteoporosis, the holes and spaces in the honeycomb are much bigger than they are in healthy bone.
Because osteoporosis is a disease of the bones, it is important to know some basic information about bones. Your bones are made up of three major components that make them both flexible and strong.
The factors that can put people at risk of osteoporosis and fractures include
Our bone health is largely dependent on the genes we inherit from our parents. In fact, if one of your parents has broken a hip, you may be more susceptible to developing osteoporosis and fragile bones.
Men and women over 60-years-old are at higher risk of osteoporosis than younger people. Nevertheless, it is possible to have osteopenia (low bone mass) or osteoporosis at a much earlier age.